Nishino Hiroto, Okuno Masayuki, Seo Satoru, Toda Rei, Yoshino Kenji, Kasai Yosuke, Satoh Motohiko, Iwaisako Keiko, Taura Kojiro, Hatano Etsuro
Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan;
Anticancer Res. 2021 Apr;41(4):1803-1810. doi: 10.21873/anticanres.14946.
BACKGROUND/AIM: Sinusoidal obstruction syndrome (SOS) after neoadjuvant chemotherapy with oxaliplatin for colorectal liver metastases (CRLM) has been reported to lead to early recurrence. This study investigated the effects of SOS on the development of CRLM in a rat model.
RCN-H4 cells were injected into the spleen or liver of ten monocrotaline-treated (SOS group) and ten untreated (control group) rats. The number and size of liver tumors were compared between the groups.
The number of liver tumors in the splenic RCN-H4 injection model was significantly higher in the SOS group than in the control group (332±213 vs. 16±5, p=0.029); however, the largest tumor diameter in the hepatic model was similar between groups (6.2±1.8 vs. 6.4±2.4 mm, p=0.87).
SOS promotes CRLM development by splenic RCN-H4 cell injection. This might be due to the higher incidence of cancer cell implantation into the liver.
背景/目的：据报道，奥沙利铂新辅助化疗治疗结直肠癌肝转移（CRLM）后发生的窦性阻塞综合征（SOS）会导致早期复发。本研究在大鼠模型中研究了SOS对CRLM发展的影响。
将RCN-H4细胞注射到10只接受野百合碱治疗的大鼠（SOS组）和10只未接受治疗的大鼠（对照组）的脾脏或肝脏中。比较两组之间肝肿瘤的数量和大小。
在脾内注射RCN-H4细胞的模型中，SOS组的肝肿瘤数量显著高于对照组（332±213对16±5，p=0.029）；然而，肝内模型中最大肿瘤直径在两组之间相似（6.2±1.8对6.4±2.4mm，p=0.87）。
通过脾内注射RCN-H4细胞，SOS促进CRLM的发展。这可能是由于癌细胞植入肝脏的发生率较高。
